Physician profile
Larry Siu
NPI 1972765675
$11,020.13
in general payments reported to CMS, 2019-2025
43 companies · $2,390 in 2025
The $2,390 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $656 · 2021: $1,175 · 2022: $1,794 · 2023: $1,985 · 2024: $1,814 · 2025: $2,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,142 · Education: $46.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,141.88 |
| Education | $46.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,023.04 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,085.61 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $714.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $672.84 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $414.36 | 2019-2025 | Stelara, Tremfya, Simponi |
| Qol Medical, LLC | $413.61 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $404.66 | 2019-2024 | Linzess |
| Ardelyx, INC. | $299.47 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $272.74 | 2019-2025 | Ocaliva |
| Celgene Corporation | $268.91 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $226.76 | 2023-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $216.56 | 2021-2023 | |
| Gilead Sciences, INC. | $193.75 | 2019-2024 | |
| Celltrion USA INC. | $185.93 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Lilly USA, LLC | $163.77 | 2023-2025 | Omvoh |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $162.08 | 2023-2025 | Qsymia, Pancreaze |
| Braintree Laboratories, INC. | $133.79 | 2022-2025 | Sutab |
| E.R. Squibb & Sons, L.L.C. | $124.05 | 2022 | |
| Allergan, INC. | $116.69 | 2019 | |
| Ferring Pharmaceuticals INC. | $91.22 | 2022-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $71.65 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $70.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $68.86 | 2023 | |
| Medtronic, INC. | $57.81 | 2024-2025 | Endoflip |
| Boston Scientific Corporation | $57.51 | 2021-2025 | Overstitch Endoscopic Suturing System |
| Regeneron Healthcare Solutions, INC. | $53.34 | 2023-2024 | Dupixent |
| Evoke Pharma, INC. | $52.19 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $51.07 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $50.25 | 2024-2025 | Voquezna |
| Capsovision, INC. | $37.68 | 2023-2024 | Capsocam Plus |
| Exact Sciences Corporation | $29.71 | 2025 | The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $29.60 | 2020 | |
| Redhill Biopharma INC. | $28.58 | 2020-2021 | |
| Pentax of America, INC. | $26.00 | 2025 | Pentax Medical, Inspira, C2 Cryoballoon |
| Ambu INC. | $23.60 | 2020 | |
| Blueprint Medicines Corporation | $23.50 | 2025 | Ayvakit |
| Sanofi Pasteur INC. | $18.05 | 2023 | |
| Fresenius Kabi USA, LLC | $16.68 | 2023 | Idacio |
| Organon LLC | $15.45 | 2024 | |
| Ucb, INC. | $14.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2023 | Cyltezo |
| Cumberland Pharmaceuticals, INC. | $13.35 | 2022 | |
| Anx Robotica Corp | $11.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Siu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.